APOLLOHOSP8,894.00

Apollo Hospitals Enterprise Ltd.

· Pharma & Health
₹ CrorePeersFORTISMAXHEALTHMEDANTASUNPHARMACIPLADRREDDYDIVISLABTORNTPHARMMcap ₹1.28L Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
APOLLOHOSP
FY26
FORTIS
FY26
MAXHEALTH
FY26
MEDANTA
FY26
Peer
Median
Valuation — at last close
P/E65.86×65.36×69.66×70.35×69.66× -5%
P/B12.82×6.70×9.36×9.83×9.36× +37%
EV/EBITDA34.95×33.84×46.08×43.75×43.75× -20%
Market Cap₹1.28L Cr₹68,097 Cr₹1.01L Cr₹39,148 Cr₹68,097 Cr +88%
Growth
Revenue CAGR 3Y14.94%13.17%22.43%17.85%17.85% -16%
Revenue CAGR 5Y19.03%17.76%27.30%22.53% -16%
Net Income CAGR 3Y33.35%18.91%9.34%19.33%18.91% +76%
Revenue YoY (latest Q)20.56%17.46%16.70%26.50%17.46% +18%
Net Income YoY (latest Q)38.41%2.26%4.87%-1.09%2.26% +1600%
Profitability
EBITDA Margin14.94%22.84%26.79%20.84%22.84% -35%
Net Income Margin7.94%11.66%17.23%12.56%12.56% -37%
Return on Common Equity19.47%10.25%13.42%13.97%13.42% +45%
Return on Capital Employed18.41%11.81%11.94%13.20%11.94% +54%
Return on Assets9.02%6.67%8.37%9.38%8.37% +8%
Credit & Quality
Total Debt/Equity0.57×0.28×0.32×0.30×0.30× +90%
Interest Coverage6.44×5.20×7.64×8.80×7.64× -16%
Scale — latest FY
Revenue / Total Income₹25,229 Cr₹9,128 Cr₹8,373 Cr₹4,410 Cr₹8,373 Cr +201%
Net Income₹2,003 Cr₹1,064 Cr₹1,442 Cr₹554 Cr₹1,064 Cr +88%
Total Assets₹22,197 Cr₹15,966 Cr₹17,231 Cr₹5,905 Cr₹15,966 Cr +39%
EPS₹135.04₹13.8₹14.83₹20.71₹14.83 +811%
Book Value per Share₹693.64₹134.69₹110.43₹148.29₹134.69 +415%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 146%.